RETA / Retatrutide 5MG

Retatrutide (LY3437943), commonly referred to as RETA, is an investigational peptide being studied for its activity at three receptors: GLP-1, GIP, and glucagon. This combination distinguishes retatrutide from compounds that primarily target the GLP-1 pathway.

• Metabolic Signaling: Investigated for effects on glucose and energy metabolism.
• Appetite Regulation: Studied in relation to food intake and appetite signaling.
• Insulin Sensitivity: Examined in metabolic research.
• Energy Expenditure: Investigated for potential effects on energy-use pathways.
• Body Weight: Studied in clinical trials involving body weight and body composition.
• Cardiometabolic Research: Investigated for effects on various metabolic markers.

Retatrutide is being studied in clinical and preclinical research examining metabolic signaling, appetite regulation, glucose control, energy expenditure, and body composition.

Clinical research has reported changes in body weight and metabolic measures, but these findings are part of ongoing investigation and should not be interpreted as established therapeutic outcomes for individual use.

FOR RESEARCH USE ONLY.

Product Strength: 5MG